Moderna Experiences Sharp Valuation Reset
Moderna shares plunged following a historic rally, erasing approximately $14.2 billion from the biotechnology company's market value as investors reassessed valuations created by its cancer-treatment breakthrough. MRNA traded near $138.89 at 10:31 a.m. ET on Thursday, dropping 20.35% from Wednesday's closing price of $174.38. During the session, the stock fell as low as $136.35.
The decline reduced Moderna's implied market capitalization from roughly $69.62 billion to $55.45 billion, based on approximately 399.24 million outstanding shares. This followed an extraordinary session in which the stock surged 177% from Tuesday's close of $62.96 to $174.38 on Wednesday, reaching an intraday high of $176.66.
Volatility in Tokenized MRNAon Markets
Market volatility was even more pronounced in the tokenized market. Moderna's Ondo tokenized stock, MRNAon, reached an all-time high of $193.43 before dropping to $136.20—a peak-to-trough decline of approximately 29.6%.
The token traded near $139.84, remaining 27.7% below its record high with roughly $567,000 in 24-hour trading volume and a reported market capitalization of about $358,000. This token market capitalization represents the circulating MRNAon supply and is distinct from Moderna's corporate market capitalization. The price sequence combines two different instruments, utilizing Nasdaq closing prices for the $62.96 baseline and MRNAon figures for the $193.43 peak and $136.20 low.
The pullback coincided with MEXC listing MRNAON/USDT for spot trading on August 20, expanding accessible venues for tokenized-stock traders.
Surpassing Wall Street Targets and Unreleased Data
No new clinical setbacks were announced prior to the Thursday decline. Instead, the reversal reflected profit-taking and concerns that Wednesday's rally pushed Moderna beyond updated analyst valuations. UBS raised its target to $150, Bank of America increased its target to $170 while upgrading the stock to Neutral, Goldman Sachs lifted its target to $120, and Morgan Stanley raised its forecast to $89.
Moderna's Wednesday close of $174.38 exceeded all four targets, including Bank of America's Street-high forecast. At the time of reporting, MRNA remained above the latest targets from UBS, Goldman Sachs, and Morgan Stanley.
The underlying clinical development stems from a Phase 3 INTerpath-001 trial conducted by Moderna and Merck, which evaluated Keytruda alongside Moderna's personalized mRNA treatment, intismeran autogene, across 1,137 patients with high-risk stage IIB-IV melanoma. While the trial met its primary recurrence-free survival endpoint and a key secondary endpoint, the companies released only topline findings without disclosing hazard ratios, absolute recurrence rates, or complete numerical efficacy results.
Despite the pullback, MRNA remained approximately 121% above its August 18 closing price, and MRNAon stayed up about 129% over a seven-day period. Upcoming catalysts include the release of complete Phase 3 datasets, medical conference presentations, and subsequent regulatory discussions.
